Medical Health & Life Science Research News

Global biologics drug discovery market to reach $22.7 billion by 2025

Medical Market Research

The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer's & many others, are higher among the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis would grow to 21% by 2040 from the current value of 15%. The prevalence of osteoarthritis increases with age and is more than 80% in people aged 75 years & above. The prevalence of genetic diseases & cancer has been on a rise in the recent years. A large number of biologic drugs are being used as treatment options for diabetes, genetic diseases & cancer as they are considered to be safe & efficacious.

According to a new market intelligence report by BIS Research, titled "Global Biologics Drug Discovery Ma…recast, 2017-2025", the global biologics drug discovery market was estimated to be $8.9 billion in 2016 and is estimated to grow over $22.7 billion by 2025. The introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine is expected to fuel the demand for biologics drugs in the future.

Browse 49 market Data Tables and 202 Figures spread through 358 Pages and in-depth TOC on "Global Biologics Drug Discovery Market"

The biologics market presents with opportunities to change the treatment options. The development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy and bio-betters presents opportunities for the further growth of the biologics drug discovery market.

According to Pushplata, an analyst at BIS Research, "Biologics are expected to contribute 50% to the sales of the top 100 products during the forecast period. This will lead to increased investment in the global biologics drug discovery market in future.

The largest contributor to the revenue was lead optimization. The market for lead optimization is expected grow at a CAGR of 10.5% from 2017 to 2025.

Among all the technologies, the major contributor to the lead optimization segment is ADME/PKPD studies. The ADME/PKPD studies were estimated to contribute $1.66 billion in 2016."

Research Highlights:

  • Major contributor towards the market in 2016 was the lead optimization phase. The market for lead optimization was estimated to be $4219.93 million in 2016.
  • In-house market for the global biologics drug discovery was estimated to be $6.5 billion in 2016 however, the CAGR was highest for the out-sourced manufacturing
  • Monoclonal antibody is anticipated to be the major contributor to the market. The market for the drug discovery of monoclonal antibody is expected to reach $10.7 billion by 2025.
  • Geographically, the largest contributor to the growth of the global biologics drug discovery market was found to be North America due to the presence of pharmaceutical companies involved in R&D of biologics.

         Source: BIS Research Analysis

Sample Report:

This market intelligence report provides a multidimensional view of the global biologics drug discovery market in terms of market size and growth potential. This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

The study considers the growth-share matrix model for a comprehensive study of the global biologics drug discovery market and assesses the factors governing the same.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with recent market activities such as product launches, regulatory clearance, and certifications, partnerships, collaborations, business expansion as well as mergers and acquisitions etc. The research report provides a comprehensive analysis of product sales, manufacturers and trend analysis by segments and demand by geographical regions.

This report is a meticulous compilation of research on more than 150 players in the market ecosystem and draws upon insights from in-depth interviews with key opinion leaders of more than 60 leading companies, market participants, and vendors. The report also profiles 28 companies including many key players such as GenScript, F.

Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, AbbVie Inc., Amgen Inc., Lilly, Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG.

News From

BIS ResearchBIS Research
Category: Market Research Publishers and RetailersCompany about: As an Owl on top of the Globe (Our Logo), BIS Research is continuously scanning, analyzing, and predicting emerging technology areas and reporting the same for your business growth. BIS Research is a global technology research and advisory company which focuses on the emerging trends in technology which are likely to disrupt the dynamics of the market. We strive to provide information about such uncharted territories to our clients so as to facilitate their decision making process. BIS Researc ...
This email address is being protected from spambots. You need JavaScript enabled to view it.